Rigel hit with an­oth­er tri­al set­back as lead drug fos­ta­ma­tinib fails PhII

Rigel’s roller coast­er ride of ad­vances and set­backs con­tin­ued this morn­ing with the news that its drug fos­ta­ma­tinib failed a mid-stage study in IgA nephropa­thy, flunk­ing the pri­ma­ry end­point.

In­ves­ti­ga­tors at the biotech $RIGL have been steer­ing through a se­ries of close hits and miss­es in the clin­ic, send­ing its shares yo-yoing over the past two years. The drug did not pro­duce a sig­nif­i­cant mean change in pro­tein­uria com­pared to a place­bo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.